Background: Children are considered a potentially vulnerable population for Zika virus infection. However, data on paediatric Zika virus infection are sparse. Methods: We analysed data from Colombia's national surveillance system during the 2015-2016 Zika virus outbreak on patients meeting the clinical case definition of Zika virus disease (ZVD) among children aged 1 month to 18 years to estimate incidence by demographic characteristics and characterize the occurrence of selected complications. Results: Between August 14, 2015, and May 28, 2016, there were 18 576 reported cases of postnatal ZVD among children aged 1 month to 18 years. Laboratory testing was prioritized for high-risk patients (infants, pregnant women, adults aged ≥65 years, and persons with serious co-morbidities); among 1655 that were tested by realtime reverse transcriptase polymerase chain reaction, 1207 (72.9%) were positive. The cumulative incidence of reported ZVD was 114.4 per 100 000. The incidence differed by sex, depending on age group; the largest difference was observed for 15-18 year olds, with females having a higher incidence than males (cumulative incidence ratio 2.5, 95% confidence interval 2.3, 2.7). At the time of report to the surveillance system, 631 patients (3.4%) were hospitalised and 96 (0.5%) had a report of an accompanying neurological diagnosis, including Guillain-Barr e syndrome in 40 patients. Conclusions: Only a small proportion of reported paediatric ZVD cases in Colombia were hospitalized or had reported neurological conditions following ZVD. However, the potential for some serious outcomes demonstrates the importance of preventing Zika virus infection in children.
and French Polynesia. 3 Since 2014, however, outbreaks have been reported in an increasing number of countries, including large outbreaks in Brazil 4 and Colombia. 5 Active mosquito-borne Zika virus transmission has been reported in 48 countries and territories in the Americas, including in the United States in southern Florida and Texas near the United States-Mexico border. 6, 7 Knowledge about Zika virus infection is rapidly evolving as the epidemic expands through the Americas and beyond. A major source of concern is Zika virus infection among pregnant women, as congenital Zika virus infection can cause severe birth defects. 8 Because the Zika virus is neurotropic 9 and neurologic development of children continues through adolescence, 10 children are also considered a potentially vulnerable population for Zika virus infection. Data on Zika virus infection in children, however, are sparse. Available data suggest that Zika virus infections among children are similar to infections in adults and are generally mild or asymptomatic. 11 Although cases of Guillain-Barr e syndrome (GBS) were not reported among children in the outbreak in French Polynesia 2 or among paediatric cases reported from U.S. states, 12 neurological conditions including GBS and encephalomyelitis have been described among children with Zika virus infection in Brazil. 13 In early 2016, there were only eight published reports on a total of 14 cases of Zika virus infection in children. 11, 14, 15 A September 2016 report of symptomatic paediatric Zika virus disease (ZVD) cases in the United States included 158 cases. 12 Additional information on Zika virus infection in children could enhance our understanding of the epidemic and identify potential risk factors for complications of paediatric infection. The objectives of this analysis were to calculate the incidence of ZVD and the occurrence of selected complications among children and adolescents in Colombia.
Methods
Colombia has a robust, passive, national surveillance system for notifiable diseases, the Sistema Nacional de Vigilancia de Salud (Sivigila), implemented by the Instituto Nacional de Salud (INS) in collaboration with the Ministry of Health. Sivigila surveillance methods have been described previously. 16 Briefly, Sivigila collects information on a multitude of reportable conditions, including several arboviral infections, by relying on the departmental and district health offices to report this information in a timely and complete manner. For ZVD surveillance, Sivigila collects information reported by health care providers to departmental and district health offices on patients with symptoms consistent with ZVD based on the current case definition; laboratory confirmation is not required for ZVD case reporting. Surveillance for symptomatic ZVD began in August 2015 and immediate reporting became mandatory in October 2015. The surveillance data presented were collected as part of public health practice and are, therefore, exempt from institutional review board review. The clinical case definition for ZVD changed over the reporting period; initially the required symptoms were fever and at least one of the following: nonpurulent conjunctivitis, headache, rash, pruritus or arthralgia, with no known alternate aetiology. This definition was revised in December 2015 to require fever plus rash and at least one of the symptoms listed above, myalgia, or malaise, with no known alternate aetiology. Specific symptom data, however, are not routinely collected by the national surveillance system. Supplementary data on neurological complications -date of symptom onset and primary International Classification of Disease, Version 10 (ICD-10) code -were also collected for all ZVD cases reported to Sivigila. Five of the diagnoses reported as neurological conditions were not plausibly linked to the reported Zika virus infection (structural cranial defects present within 1-3 days of ZVD symptom onset) and were excluded from the description of reported cases with accompanying neurological symptoms.
Because of the magnitude of the outbreak, laboratory testing was prioritized for specific risk groups: infants, pregnant women, adults aged ≥65 years, and persons with serious co-morbidities. Therefore, laboratory testing for most children and adolescents with reported ZVD was not performed. Laboratory confirmation was available for a small proportion of reported cases from serum samples using real-time reverse transcriptase polymerase chain reaction (rRT-PCR) performed by the INS laboratory or a laboratory designated by INS. By protocol, serum samples were to be tested by rRT-PCR if collected within 7 days of symptom onset, although some testing of older samples occurred (4.9%). Samples that lacked laboratory evidence for Zika virus by rRT-PCR were also tested for dengue and chikungunya virus RNA by rRT-PCR. Antibody testing for Zika virus was not available in Colombia during the study period.
We analysed data on reported paediatric and adolescent cases of ZVD aged 28 days to 18 years with symptom onset from August 14, 2015 -the date of symptom onset for the first reported paediatric casethrough May 28, 2016. Neonates less than 28 days of age (i.e. 1 month) were excluded from this report (n = 406) because additional follow-up information is needed to clearly distinguish congenital and postnatal infections.
Statistical analysis
We characterized paediatric ZVD cases reported to Sivigila by laboratory confirmation status, age group (1 month to <1 year, 1 to <3 years, 3 to <7 years, 7 to <11 years, 11 to <15 years, and 15 to <19 years), sex, pregnancy status, department (i.e. state/district) or major municipality of occurrence, ethnicity, and insurance type. We calculated cumulative incidence by categories of age group and sex and by Department, by dividing case counts in each category by the corresponding base population, derived from national Census data; cumulative incidence rates are presented per 100 000 population. We used Poisson regression to calculate cumulative incidence ratios (CIR) and 95% confidence intervals (CIs) comparing females with males. We also compiled and summarized information on patients who were hospitalized or had died at the time of the report and on patients reported with accompanying neurological conditions. No additional clinical or epidemiological data were available, except for three of the deaths, as described below.
Results
There were 18 576 reported cases of symptomatic ZVD among children and adolescents aged 1 month to 18 years in Colombia with dates of symptom onset between August 14, 2015, and May 28, 2016 (Table 1) . A total of 1655 ZVD patients had serum rRT-PCR results, 1207 (72.9%) of which had laboratory evidence of Zika virus infection. Across age groups, sex, ethnicity, residence, and insurance type, approximately 70% of tested ZVD patients had positive results for Zika virus infection. Among the 448 patients without positive Zika virus results, none had laboratory evidence of dengue or chikungunya virus infection by rRT-PCR. The median number of days between symptom onset and serum sample collection was 2 for patients with positive and negative test results. There were 1700 pregnant adolescents with reported ZVD, 16 .1% of all females with reported ZVD. Among 634 pregnant adolescents who were tested for Zika virus infection, 481 (75.9%) had laboratory confirmation of Zika virus infection. The majority of all reported ZVD cases were among children who lived in a municipal township (85.0%), were of Mestizo/white ethnicity (96.4%), and whose families were either able to pay into the government health care system or had subsidized insurance (46.8% and 41.6%, respectively).
The overall cumulative incidence of reported ZVD among children was 114.4 per 100 000 ( Table 2 ). The highest cumulative incidence of reported ZVD cases was among children 1 month to <1 year of age (257.3 per 100 000), followed by adolescents 15-18 years of age (137.3 per 100 000). Overall, there was a modestly higher cumulative incidence among female paediatric reported ZVD patients (CIR for females relative to males 1.3, 95% CI 1.2, 1.3). However, this pattern varied by age group. Female children age 1-2 years had a lower ZVD incidence than males in that age group (CIR 0.9, 95% CI 0.8, 1.0), while 7-to 10-yearold females had a higher incidence of ZVD compared with males (CIR 1.1, 95% CI 1.1, 1.2). The largest difference was observed for adolescents age 15-18 years, with females having a higher incidence than males (CIR 2.5, 95% CI 2.3, 2.7).
Although reported ZVD cases had symptom onset dates as early as August 14, 2015 (epidemiologic week 32), a rapid increase in reported ZVD cases began during the week of September 27 to October 3, 2015 (week 39; n = 38) and peaked between January 31 and February 6, 2016 (week 5; n = 1391; Figure 1 ). There were 419 reported ZVD cases among children with symptom onset during the week of May 22 to 28, 2016 (week 21), the last week included in this report. The departments in which the highest cumulative incidences of reported paediatric ZVD were observed were San Andr es (1386.9 per 100 000), Casanare (518.8 per 100 000), and Norte de Santander (445.5 per 100 000) (Figure 2 ). The greatest number of reported paediatric ZVD cases occurred in Valle del Cauca (n = 3870), Norte de Santander (n = 2166), and Huila (n = 1387). Ninety-six patients with reported ZVD also had a report of an accompanying neurological diagnosis (0.5%) (Table 3) , although reported diagnoses have not been verified. Onset of neurological symptoms most often occurred concurrently with the onset of ZVD symptoms (median 0 days; range 0-36 days after ZVD symptom onset). The age distribution of patients with accompanying neurological diagnoses was skewed older than the overall population. While children aged 1 month to 6 years comprise 38.3% of the reported paediatric ZVD cases, they account for only 29.2% of reported ZVD patients with a report of an accompanying neurological diagnosis. Although a preponderance of females was observed among all reported cases (56.8% females), among reported cases with accompanying neurological complications, there was a male preponderance (59.4% males). The majority of patients with reported ZVD and neurological complications were hospitalized at the time of report (n = 82; 85.4%). GBS was reported for 40 cases; an additional 24 reported ZVD cases had a diagnosis of polyneuropathy. Viral encephalitis was reported for 17 ZVD cases in this population. Among 25 patients with reported neurological complications who received laboratory testing, 12 (48%) had laboratory evidence of Zika virus.
A total of 631 patients with reported ZVD (3.4%) were hospitalized at the time they were reported to the surveillance system. Infants <1 year of age had the highest percentage of reported ZVD patients who were hospitalized (5.2%; n = 106) relative to other age groups, although 9.1% (n = 155) of pregnant adolescents were hospitalized at the time of report. There were nine deaths reported among patients aged 1 month to 18 years with ZVD; seven of these deceased patients were tested for Zika virus infections, and six (86%) were positive among those tested. Three of the deceased patients had ICD-10 codes indicating the cause of death as severe dengue. These three deaths had laboratory evidence of Zika virus infection, but were also individually investigated by INS, providing additional information about their cause of death; one of the deaths was attributed to bacterial meningitis, one was attributed to acute myeloid leukaemia, and one was determined to be due to complications of GBS, secondary to Zika virus infection. Additional information was not available for the remaining six deaths which included three with laboratory evidence of Zika virus infection, two who were not tested, and one who had negative results for Zika. These six were attributed in their initial report to the surveillance system as deaths due to acute respiratory failure (N = 2), other specified mosquito-borne viral fever, unspecified meningitis, unspecified cardiac arrest, and unspecified hepatic failure. One of these deaths also occurred in a patient who was reported to have GBS and was negative for Zika virus infection. No deaths occurred among pregnant adolescents.
Comment
In the first nine and a half months of the Zika virus epidemic in Colombia, there were 18 576 children and adolescents aged 1 month to 18 years reported to the national surveillance system as meeting the clinical case definition for ZVD, making this the largest population of reported paediatric ZVD cases presented to date, with a cumulative incidence of 114.4 per 100 000. The distribution of reported paediatric ZVD cases over time was consistent with the pattern observed for all reported ZVD cases in Colombia. 16 In order to be reported to the surveillance system, a patient had to be symptomatic, with symptoms matching the case definition, and to have sought health care. The prevalence of symptomatic disease among people with Zika virus infection is not known; in the previous outbreak in the State of Yap, it was estimated that approximately 80% of cases were asymptomatic, 2 but data from a serosurvey in French Polynesia suggest school-aged children with Zika virus infection may be more likely to display symptoms than the general population. 17 Because the reported cases in this analysis represent only cases of symptomatic Zika virus disease, the total number of Zika virus infections including asymptomatic infections among children and adolescents during this time in Colombia is unknown. In addition, symptomatic cases for which health care services were not sought would also lead to an underestimate of the prevalence, because reports to Sivigila are dependent on report from a health care provider. The symptoms and course of ZVD is typically milder than other arboviruses circulating in Colombia, 16 including dengue and chikungunya, which may have reduced the likelihood of seeking health care for ZVD symptoms.
There are a number of additional limitations to this analysis of existing surveillance data. Because laboratory confirmation was not available for most reported cases, there are likely some cases that were actually due to other causes but were reported with ZVD to the surveillance system based on their symptoms. While most paediatric ZVD cases were not tested for Zika virus infection, approximately 70% of those tested were confirmed across all categories. During the time period covered in this report, there were nearly 90 000 cases of ZVD reported to Sivigila among all ages. 18 Given the size of the outbreak and the relatively mild clinical course for most people, priority for laboratory testing was appropriately given to specific groups with a higher likelihood of poor outcomes from ZVD, specifically infants, pregnant women, adults aged over 65 years, and persons with serious co-morbidities. Among the 1655 patients for whom laboratory testing for Zika virus infection was Bogotá D.C. (27.1%) might not have had Zika infection, but because it can be difficult to specify the exact date of symptom onset due to the generally mild symptoms of ZVD, these specimens may have been collected after Zika virus RNA cleared from the patient's bloodstream; rRT-PCR tests for Zika virus infection are most sensitive in the week after symptom onset. 1 Because symptoms of ZVD can be similar to milder presentations of other arboviruses that are circulating in Colombia and other illnesses with overlapping symptoms, we cannot rule out misclassification of patients without laboratory confirmation of Zika virus infection. The case definitions used by Sivigila differ from those used in the United States, 19 particularly regarding the requirement for laboratory confirmation, which makes direct comparisons challenging. For example, 22% of laboratory-confirmed paediatric ZVD cases in the United States did not report fever, 12 while fever was required by the Sivigila case definition in Colombia. We observed a 2.5-fold higher cumulative incidence of reported ZVD among female patients aged 15-18 years compared to male patients of the same age, which cannot be explained by laboratory testing bias due to pregnancy because we included all reported cases of ZVD, not only those that were laboratory confirmed. However, because almost half of females in this age group were pregnant (n = 1597, 46.6%), it is probable that they were more likely to seek care because of concerns about adverse pregnancy outcomes associated with Zika virus infection during pregnancy. If pregnant adolescents are excluded, the CIR comparing female and male patients in this age group is still elevated (1.3, 95% CI 1.2, 1.4), which may be explained by concern over the possibility of pregnancy or sexual transmission of Zika virus infection from males to females due to persistence of Zika virus in semen, or could be due to differing health care seeking behaviours by sex. 20 A recent report describing 158 cases of postnatally acquired laboratoryconfirmed ZVD among U.S. children also found a higher incidence of ZVD among female patients aged 15-17 years relative to males in that age group. 12 In addition, a previous report of ZVD in Colombia using Sivigila data showed a significantly higher cumulative incidence among females compared with males for all adult age groups. 16 Additional targeted studies are needed to fully understand the reasons for the observed higher incidence of ZVD among females. GBS, an acute inflammatory polyneuropathy typically triggered by infection, 21 was previously linked to Zika virus infection during the 2013-2014 outbreak in French Polynesia 22 and more recently in Colombia. 23 We observed that among children and adolescents, there were 2.2 reported cases of GBS per 1000 reported cases of ZVD, a much higher incidence than previously published estimates in general paediatric populations (e.g. 0.74-1.15 per 100 000 in a paediatric Chinese population, 1.02-1.21 per 100 000 in a paediatric Swedish population, and 0.8 per 100 000 in a paediatric Australian population), [24] [25] [26] but similar in magnitude to that observed among all reported ZVD cases in Colombia (4.4 per 1000 cases of reported ZVD). 23 Although diagnostic criteria are available to distinguish GBS from other causes of polyneuropathy, 27 the degree to which these criteria were used in diagnosing paediatric ZVD patients reported to Sivigila with GBS remains unclear; no confirmatory information was available to verify the GBS diagnosis and only a single ICD-10 code was included in the report. It is noteworthy that in addition to 40 reported ZVD patients with GBS, there were an additional 21 ZVD patients with a neurological diagnosis code for unspecified polyneuropathy. GBS in children can cause pain, muscle weakness, acute flaccid paralysis, and in some cases may require ventilator support to treat respiratory failure. In our data, older children (>10 years) made up a larger proportion of paediatric ZVD patients reported with neurological conditions than total paediatric ZVD patients. However, relative to adults, GBS among children tends to result in a shorter course of illness and a more complete recovery. 28 No cases of GBS were reported among the 158 U.S. children with postnatally acquired ZVD. 12 
Conclusions
Over 18 500 infants, children, and adolescents in Colombia were reported with symptomatic ZVD over a nine-and-a-half-month period in 2015 and 2016. Laboratory confirmation was not available for the majority of reported cases, and many Zika virus infections will not have been captured in these surveillance data. While ZVD is considered a relatively mild disease, severe complications can occur, and the effects of paediatric Zika virus infection on development are unknown. Very few deaths occurred among reported paediatric ZVD cases in Colombia and only a small proportion were hospitalized or had reported neurological conditions following ZVD; most of these serious outcomes reported could not be clearly linked to Zika virus infection. However, the potential for some serious outcomes demonstrates the importance of preventing Zika virus infection in children.
